May 18, 2022
Dr. Mark Berman is the Chief Medical Officer at Better Therapeutics, using a prescription digital therapeutic to treat diseases caused by human behavior, particularly type II diabetes. While PDT model might be expected to be effective with younger patients, clinical trial data is revealing that older patients 60+ are getting the most benefit in blood sugar reduction from this approach.
Mark elaborates, "We are, at Better Therapeutics, trying to pioneer a prescription digital therapeutics platform with the intent of treating a whole host of cardiometabolic conditions, starting first with type II diabetes. Then moving on to other related cardiometabolic conditions that all share their roots in health behaviors that really drive the pandemic of disease that we're seeing in cardiometabolic health. And so, at Better Therapeutics, we're bringing about this platform to enable scalable means of treating those root causes of cardiometabolic conditions."
"The notion of prescription digital therapeutic is that instead of prescribing yet another drug to help those types of patients, they're going to prescribe an FDA regulated mobile medical app, a prescription digital therapeutic, which is easy to fill, and it comes directly onto the patient's smartphone. And from there, it's the job of the digital therapeutic to really personalize the therapy for the patient. We don't believe that the providers have the time or the ability to really get very granular into the nature of the behavioral therapy. We really need to rely on the digital therapeutic to do that personalized work about what behaviors to target and how to be effective in each patient."
@Better_TX #DigitalTherapeutics #DigitalHealth #PDT #PrescriptionDigitalTherapeutic #Type2Diabetes #MobileHealth
